Subscribe To
Us fda approves pfizer's hair loss drug
The U.S. Food and Drug Administration has approved Pfizer Inc's drug to treat hair loss caused by an autoimmun...
June 23, 2023, 6:19 pm
Pfizer's alopecia drug for teens and adults approved by fda
Pfizer Inc. PFE, -1.11% said late Friday that its drug ritlecitinib, sold under the brand name of Litfulo, has been approved by the U.S. Food and Drug...
June 23, 2023, 6:02 pm
Vera therapeutics shares surge on positive igan trial results
Vera Therapeutics, Inc shares climbed 20% to $15.38 on Tuesday after the late-stage biotechnology company revealed positive trial results for atacicep...
June 20, 2023, 3:56 pm
Eli lilly to acquire dice therapeutics for $2.4 billion in autoimmune treatment push
Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for ...
June 20, 2023, 8:29 am
Eli lilly to buy dice therapeutics in $2.4 billion autoimmune disease push
Lilly said its acquisition of Dice for $48 a share would allow it to leverage the group's developing treatments for chronic diseases in immunology....
June 20, 2023, 7:06 am
Eli lilly to buy dice therapeutics in $2.4 billion deal
Eli Lilly and Co will buy Dice Therapeutics Inc in an all-cash deal worth about $2.4 billion to boost its auto...
June 20, 2023, 7:00 am
Gri bio (nasdaq: gri) to participate in the healthcare virtual conference presented by maxim group llc and hosted by m-vest
– Live webcast fireside chat on Thursday, June 22nd at 12:00 PM ET LA JOLLA, CA, June 15, 2023 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“...
June 15, 2023, 12:45 pm
Astrazeneca (azn) & quell to co-develop autoimmune cell therapies
AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major ...
June 12, 2023, 10:58 am
Immunocore holdings: unlocking the immune system's hidden potential
Immunocore Holdings is a leading biotech firm with a promising pipeline of T cell receptor-based bispecific immunotherapies for cancer, ...
June 11, 2023, 3:49 am
Astrazeneca signs $2 bln agreement with quell to develop cell therapies
AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that co...
June 9, 2023, 4:03 am
Astrazeneca places $85 million bet on autoimmune cell therapy with quell deal
AstraZeneca PLC (LSE:AZN) is placing an $85 million bet on the autoimmune cell therapy sector with Q...
June 9, 2023, 3:11 am
Atara biotherapeutics to participate in the goldman sachs 44th annual global healthcare conference
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its n...
June 7, 2023, 4:01 pm
Revvity (rvty) launches new system for autoimmune diagnostics
Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostic...
June 6, 2023, 1:45 pm
Landos biopharma to present at the 2023 jefferies healthcare conference
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral m...
May 31, 2023, 8:15 pm
Argenx to present at upcoming investor conferences
May 3 1 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of peop...
May 31, 2023, 1:00 am
Immunic to participate in scientific and investor conferences in june
NEW YORK , May 30, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,...
May 30, 2023, 6:30 am
Immunovant could be poised for a breakout in h2 2023
Rating: Buy-rating maintained based on IMVT-1402's unique potential and impending Phase 1 catalyst in 2H 2023. Stock Upswing: Anticipate over 200% ris...
May 24, 2023, 1:14 pm
Dice therapeutics psoriasis treatment has blockbuster potential, analysts say
Canaccord Genuity (TSX:CF, LSE:CF) analysts have initiated coverage of DICE Therapeutics, Inc, a biopharmaceutical company focused on treating chronic...
May 23, 2023, 2:56 pm
Cabaletta bio announces closing of $100 million public offering of common stock, including full exercise of option to purchase additional shares
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnol...
May 22, 2023, 8:30 pm
Alpine immune sciences to present data from ruby-1, a phase 1 study of povetacicept, at upcoming scientific congresses
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...
May 19, 2023, 4:30 pm